Clinical trials: Melanoma Stage Stage IIIB
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body.
- Conditions
- Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03727789
- Testing
- FACT Complex-targeting Curaxin CBL0137
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Melanoma, Stage IIIA Melanoma
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT00436605
- Testing
- dasatinib
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
This randomized phase II trial studies how well cabozantinib-s-malate works compared with temozolomide or dacarbazine in treating patients with melanoma of the eye (ocular melanoma) that has spread to other parts of the body and…
- Conditions
- Recurrent Uveal Melanoma, Stage III Uveal Melanoma AJCC v7, Stage IIIA Uveal Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7
- Trial name
- NCT01835145
- Testing
- Cabozantinib S-malate, Dacarbazine, Laboratory Biomarker Analysis
- Where
- 228 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7
- Trial name
- NCT03021460
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Melanoma
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
The purpose of this study is to learn about the safety and the risks of using talimogene laherparepvec in patients who already received treatment with talimogene laherparepvec in study 005/05 (NCT00769704), and to see if extended…
- Trial name
- NCT01368276
- Testing
- Talimogene Laherparepvec, Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- BioVex Limited
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer
This phase I trial studies the side effects and best dose of recombinant interleukin-15 in treating patients with melanoma, kidney cancer, non-small cell lung cancer, or head and neck cancer that has spread to other places in the…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT01727076
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma (Skin)
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
This study is being performed to evaluate the safety and efficacy of Dacarbazine and OrienX010 therapy in Untreated Patients With Unresectable Stage IIIb/IIIc or Stage IV(Mla/Mlb) Melanoma.
- Trial name
- NCT04200040
- Testing
- OrienX010 injection, Dacarbazine (DTIC)
- Where
- China
- Volunteers
- 165 people
- Sponsor
- OrienGene Biotechnology Ltd.
Melanoma
A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma
A phase IIb, multicentre, open label study to evaluate the effectiveness, safety, and tolerability of intratumoural tigilanol tiglate in adult participants with Stage IIIB to IV M1c melanoma
- Trial name
- NCT05234437
- Testing
- tigilanol tiglate
- Where
- 3 sites in Australia
- Volunteers
- 1 people
- Sponsor
- QBiotics Group Limited
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable…
- Trial name
- NCT02211131
- Testing
- Talimogene Laherparepvec, Immediate surgical resection of melanoma lesion(s)
- Where
- 46 sites in United States, Australia and 7 more
- Volunteers
- 150 people
- Sponsor
- Amgen
Melanoma, Lymph Node Cancer
CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).
- Trial name
- NCT03618641
- Testing
- CMP-001, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Diwakar Davar
Melanoma
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab
The main goal of this research study is to determine how nivolumab and nivolumab/Vidutolimod (CMP-001) combination affect the likelihood of destroying melanoma involving lymph node and/or in-transit/satellite areas.
- Trial name
- NCT04401995
- Testing
- Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Diwakar Davar
Melanoma
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma.
- Trial name
- NCT00769704
- Testing
- Talimogene laherparepvec, GM-CSF
- Where
- 83 sites in United States, Canada and 2 more
- Volunteers
- 437 people
- Sponsor
- BioVex Limited
Malignant Melanoma
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment in Stage III B/C melanoma patients.
- Trial name
- Pivotal (NCT02938299)
- Testing
- L19IL2 + L19TNF, Surgery
- Where
- 22 sites in France, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- Philogen S.p.A.
Hereditary Multiple Melanoma, Melanoma (Skin)
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma
RATIONALE: Identifying gene mutations and other risk factors in patients with melanoma and in families with a history of hereditary melanoma may help doctors identify persons at risk for melanoma and other types of cancer.
- Trial name
- NCT00450593
- Testing
- gene expression analysis, microarray analysis, molecular genetic technique
- Where
- United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Carcinoma, Melanoma
CPG 7909 Injection in Melanoma
To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.
- Trial name
- NCT00070642
- Testing
- CPG 7909 Injection, dacarbazine, Chemotherapy
- Volunteers
- 184 people
- Sponsor
- Pfizer
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma
- Trial name
- NCT02068586
- Testing
- Sunitinib, Valproic Acid, Sunitinib Malate
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
This study will evaluate the clinical and pathological response to vemurafenib and cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600 mutation-positive Stage IIIB and C melanoma.
- Trial name
- NCT02036086
- Testing
- Vemurafenib, Cobimetinib
- Where
- 3 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Sunnybrook Health Sciences Centre
Cutaneous Melanoma, Melanoma
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
This phase II trial studies the effect of a vaccine called CDX-1401 given with or without a biologic drug called CDX-301 in treating patients with stage IIB-IV melanoma.
- Conditions
- Cutaneous Melanoma, Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma
- Trial name
- NCT02129075
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)